PP-025 Stability of intravitreal bevacizumab solution in polypropylene syringes in neovascular macular degeneration

  1. Santoveña Estévez, A 2
  2. Gutiérrez Nicolas, F 1
  3. Sanchez Negrín, E 2
  4. Virgos Aller, T 1
  5. Nazco Casariego, J 1
  6. Fariña Espinosa, J 2
  1. 1 Hospital Universitario de Canarias

    Hospital Universitario de Canarias

    San Cristóbal de La Laguna, España

    ROR https://ror.org/05qndj312

  2. 2 Universidad de La Laguna

    Universidad de La Laguna

    San Cristobal de La Laguna, España

    ROR https://ror.org/01r9z8p25

European Journal of Hospital Pharmacy

ISSN: 2047-9956

Year of publication: 2015

Volume: 22

Issue: Suppl 1

Type: Article

DOI: 10.1136/EJHPHARM-2015-000639.305 GOOGLE SCHOLAR

More publications in: European Journal of Hospital Pharmacy


JCR (Journal Impact Factor)

  • Year 2015
  • Journal Impact Factor: 0.432
  • Journal Impact Factor without self cites: 0.341
  • Article influence score: 0.126
  • Best Quartile: Q4
  • Area: PHARMACOLOGY & PHARMACY Quartile: Q4 Rank in area: 246/255 (Ranking edition: SCIE)

SCImago Journal Rank

  • Year 2015
  • SJR Journal Impact: 0.193
  • Best Quartile:
  • Area: Pharmacy Quartile: - Rank in area: 18/42

Scopus CiteScore

  • Year 2015
  • CiteScore of the Journal : 0.7
  • Area: Pharmacology, Toxicology and Pharmaceutics (all) Percentile: 36


Background Bevacizumab is used by intravitreal administration as an off-label drug to treat age-related macular degeneration and other ophthalmologic diseases.Purpose To analyse the physicochemical stability of bevacizumab repackaged in 1-mL polypropylene syringes for intravitreal injection.Material and methods Bevacizumab syringes were repackaged under laminar flow. Each syringe contained 200 or 900 μL (25 mg/mL). For the stability assessment at 4°C, three storage groups of 2 repacked syringes and 2 original vials were constituted for each analysis time (0, 3, 7, 14 days). For bevacizumab characterisation a HPLC consisting of a Waters pump (600 E), an autosampler (717 plus), a dual UV detector (2487) to 214 nm, as stationary phase ShodexKW804 (8.0 mm × 300 mm) column and a mobile phase (25 mM NaH2PO4·2 H2O and 300 mM NaCl pH 7) at a flow of 1 ml/min. The size distribution of particles in the samples incubated in syringes was determined by a Zetasizer system.Results The proposed HPLC method allowed us to separate two peaks for the bevacizumab control sample, corresponding to bevacizumab monomer (mean peak) and its oligomer, with retention times of 9.8 and 8.6 min respectively. We used the evolution of the monomer peak area value to indicate the stability. For the original vials the area values remained at 100% of their initial value for 7 days storage. For repacked bevacizumab this value was maintained for 3 days. The Zetasizer particles analyser detected submicron particles whose origin could be the repacking, for the vials mean particle size (17.8 ± 4.7) nm remained constant for 15 days. For repacked syringes this value remained constant for 3 days, at day 7 we found a small% of particles with size next to 5 µm indicating probable particle contamination of unknown origin.Conclusion Our results support the physicochemical stability for 3 days at 4°C of repackaged bevacizumab for intravitreal administration.